Document is current
Any future updates will be listed below
-
Authors
Franco-Moreno, Anabel https://orcid.org/0000-0003-1061-0200
Acedo-Gutiérrez, María Soledad
Martín, Nicolás Labrador-San
Hernández-Blanco, Clara
Rodríguez-Olleros, Celia
Ibáñez-Estéllez, Fátima
Suárez-Simón, Ana
Balado-Rico, Mateo
Romero-Paternina, Ana Rocío
Alonso-Menchén, David
Escolano-Fernández, Belén
Piniella-Ruiz, Esther
Alonso-Monge, Ester
Notario-Leo, Helena
Bibiano-Guillén, Carlos
Peña-Lillo, Gabriela
Antiqueira-Pérez, Armando
Romero-Pareja, Rodolfo
Cabello-Clotet, Noemí
Estrada-Pérez, Vicente
Troya-García, Jesús
de Carranza-López, María
Escobar-Rodríguez, Ismael
Vallejo-Maroto, Nacho
Torres-Macho, Juan
-
Funding
Funding for this research was provided by:
KERN PHARMA Pharmaceutical
- License Information
-
More Information
Article History
Received: 21 November 2021
Accepted: 8 September 2022
First Online: 15 September 2022
Declarations
:
: This study is being carried out in accordance with the recommendations of the institutional Ethics in Human Research Committees. All participants will have given informed consent to one of the study investigators in accordance with the Declaration of Helsinki. Fundación para la Investigación e Innovación Biomédica (FIIB) del Hospital Universitario Infanta Leonor y Hospital Universitario del Sureste is the sponsor of EARLY-DEX COVID-19 trial. Ethical approval was obtained by the Ethics Committees for investigation with medicinal products of the Comunidad de Madrid.
: Not applicable.
: This study is funded by the pharmaceutical laboratory Kern Pharma, S.L. Dexamethasone will be provided free of charge for this study by Kern Pharma, S.L. The funding body had no input into the study design or in the writing of the manuscript.
